Australian researchers have developed a drug capable of reprogramming the immune system to fight cancer, it was announced on Thursday.
The landmark new therapy, developed by the Peter MacCallum Cancer Centre, involves removing immune cells from the body to genetically enhance them before putting them back in the body to fight cancer, Xinhua reports.
The form of immunotherapy has previously been effective in fighting blood cancers but lead scientists Phillip Darcy and Paul Beavis found a way to improve its effectiveness against solid tumours for the first time.
Darcy said that the enhanced immune cells, known as CAR T cells, have been ineffective against solid tumours which have been able to produce a metabolite called adenosine which destroys the cells.
Some tumours have even shown the ability to simply reverse the enhancements placed on the cells, making them revert to T cells which have little ability to combat the tumours.
"The suppressive tumour environment dampens down the ability of the immune cells so we needed to give the cells something extra to be able to work in those environments," Darcy told Australian media on Thursday.
Researchers successfully trialled a drug in mice that blocks the metabolite, allowing CAR T cells to effectively target tumours.
They are now planning to take the drug into phase one human trials.
--IANS
ksk/sac
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
